<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066517</url>
  </required_header>
  <id_info>
    <org_study_id>R 918/19 - CCM968</org_study_id>
    <nct_id>NCT04066517</nct_id>
  </id_info>
  <brief_title>STereotactic RadioAblation by Multimodal Imaging for VT (STRA-MI-VT)</brief_title>
  <acronym>STRA-MI-VT</acronym>
  <official_title>STereotactic RadioAblation by Multimodal Imaging for VT (STRA-MI-VT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Cardiologico Monzino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Istituto Europeo di Oncologia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Cardiologico Monzino</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of multimodal-imaging guided stereotactic body radiotherapy (SBRT) for ventricular&#xD;
      tachycardia (VT) ablation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STRA-MI-VT study is a spontaneous, open-label, not randomized, prospective clinical trial.&#xD;
&#xD;
      The objective of the study is to evaluate the safety and efficacy of SBRT in strictly&#xD;
      selected patients with refractory VT.&#xD;
&#xD;
      Multimodal cardiac imaging combined with electroanatomic mapping to provide a specific&#xD;
      patient's tailored SBRT treatment plan choosing amang different linear accelerators.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2019</start_date>
  <completion_date type="Anticipated">January 13, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 13, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking in this study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>SBRT safety during 12 month follow-up</measure>
    <time_frame>12 months</time_frame>
    <description>Serious adverse events will be defined using CTCAE v4.0 criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SBRT efficacy based on reduction of VT episodes during 12 month follow-up</measure>
    <time_frame>12 months</time_frame>
    <description>There will be 6 week blanking period after therapy to allow for ablation effect</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Health related quality of life for positive or negative changes based on score from SF-36 Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac functional changes</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiac functional changes evaluated by echocardiography ejection fraction</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Refractory Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-randomized, open label clinical trial that intends to treat with SBRT 15 patients with refractory VT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>Multimodal-imaging guided SBRT for VT ablation.</description>
    <arm_group_label>Open Label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ICD/S-ICD recipients with refractory VT&#xD;
&#xD;
          -  Not eligible for conventional catheter ablation or -in alternative- that have&#xD;
             undergone failing conventional catheter ablation attempts, refusing surgery for the&#xD;
             treatment of the arrhythmia.&#xD;
&#xD;
          -  LVEF ≥ 20%.&#xD;
&#xD;
          -  Age ≥ 50 years.&#xD;
&#xD;
          -  Signed an IRB approved written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous radiotherapy with cardiac involvement.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Active myocardial ischemia.&#xD;
&#xD;
          -  Acute revascularation in the past 120 days.&#xD;
&#xD;
          -  Acute hemodynamic instability (cardiogenic shock/NYHA IV).&#xD;
&#xD;
          -  Serious disease with presumed life expectancy less than 12 months.&#xD;
&#xD;
          -  Any condition that is deemed a contraindication in the judgment of the investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Corrado Carbucicchio, MD</last_name>
    <phone>+39 02 58001626</phone>
    <email>corrado.carbucicchio@ccfm.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valentina Catto, PhD</last_name>
    <phone>+39 02 58002856</phone>
    <email>valentina.catto@ccfm.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino, IRCCS</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corrado Carbucicchio, MD</last_name>
      <phone>+39 02 58001626</phone>
      <email>corrado.carbucicchio@ccfm.it</email>
    </contact>
    <contact_backup>
      <last_name>Valentina Catto, PhD</last_name>
      <phone>+39 02 58002856</phone>
      <email>valentina.catto@ccfm.it</email>
    </contact_backup>
    <investigator>
      <last_name>Corrado Carbucicchio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniele Andreini, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia, IRCCS</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Carbucicchio C, Jereczek-Fossa BA, Andreini D, Catto V, Piperno G, Conte E, Cattani F, Rondi E, Vigorito S, Piccolo C, Bonomi A, Gorini A, Pepa M, Mushtaq S, Fassini G, Moltrasio M, Tundo F, Marvaso G, Veglia F, Orecchia R, Tremoli E, Tondo C. STRA-MI-VT (STereotactic RadioAblation by Multimodal Imaging for Ventricular Tachycardia): rationale and design of an Italian experimental prospective study. J Interv Card Electrophysiol. 2021 Sep;61(3):583-593. doi: 10.1007/s10840-020-00855-2. Epub 2020 Aug 27.</citation>
    <PMID>32851578</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 24, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Cardiologico Monzino</investigator_affiliation>
    <investigator_full_name>Corrado Carbucicchio</investigator_full_name>
    <investigator_title>Head of Ventricular Intensive Care Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

